Unknown

Dataset Information

0

Pharmacokinetics of tralokinumab in adolescents with asthma: implications for future dosing.


ABSTRACT: AIMS:Tralokinumab, an investigational human immunoglobulin G4 monoclonal antibody, potently and specifically neutralizes interleukin-13, a central mediator of asthma. Tralokinumab has shown improvements in clinical endpoints in adults with uncontrolled asthma. The present study explored the pharmacokinetics (PK) and safety of a single tralokinumab dose, and utilized a population PK modelling and simulation approach to evaluate the optimal dosing strategy for adolescents. METHODS:Adolescent subjects with asthma, using daily controller medication, received a single subcutaneous dose of tralokinumab 300?mg. Safety, immunogenicity and PK data were collected during a 57-day follow-up. A population PK model was developed using data from the present study and prior studies in adults. Simulations were performed to evaluate dose adjustment requirements for adolescents. RESULTS:Twenty adolescents (12-17 years) were enrolled; all completed the study. No clinically relevant safety findings or antidrug antibodies were detected. PK parameters were similar to those observed in adults. PK modelling showed that body weight was a minor predictor of tralokinumab PK; after incorporating body weight into the PK model, a 15% (nonparametric 95% confidence interval 5%, 26%) lower clearance was found in adolescents compared with adults [173 (151, 209) vs. 204 (191, 229) ml day(-1)]. Simulations showed no therapeutically relevant differences in exposures between adolescent and adult populations, and similar PK profiles for weight-based (4?mg kg(-1)) and fixed (300?mg) fortnightly subcutaneous doses of tralokinumab. CONCLUSION:Single-dose administration of tralokinumab 300?mg in adolescents was well tolerated, with a PK profile similar to that in adults. Exposure predictions suggest that dose adjustment is not required for adolescents.

SUBMITTER: Baverel PG 

PROVIDER: S-EPMC4693499 | biostudies-literature | 2015 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Pharmacokinetics of tralokinumab in adolescents with asthma: implications for future dosing.

Baverel Paul G PG   Jain Meena M   Stelmach Iwona I   She Dewei D   Agoram Balaji B   Sandbach Sara S   Piper Edward E   Kuna Piotr P  

British journal of clinical pharmacology 20151001 6


<h4>Aims</h4>Tralokinumab, an investigational human immunoglobulin G4 monoclonal antibody, potently and specifically neutralizes interleukin-13, a central mediator of asthma. Tralokinumab has shown improvements in clinical endpoints in adults with uncontrolled asthma. The present study explored the pharmacokinetics (PK) and safety of a single tralokinumab dose, and utilized a population PK modelling and simulation approach to evaluate the optimal dosing strategy for adolescents.<h4>Methods</h4>A  ...[more]

Similar Datasets

| S-EPMC7566350 | biostudies-literature
| S-EPMC4386948 | biostudies-literature
| S-EPMC4024352 | biostudies-literature
| S-EPMC6765695 | biostudies-literature
| S-EPMC7347085 | biostudies-literature
| S-EPMC3561510 | biostudies-literature
| S-EPMC6260153 | biostudies-literature
| S-EPMC5365666 | biostudies-literature
| S-EPMC8519819 | biostudies-literature
| S-EPMC3630454 | biostudies-literature